Nucleic Acid Therapeutics CDMO Market (2026 - 2033)

Nucleic Acid Therapeutics CDMO Market Summary

The global Nucleic Acid Therapeutics CDMO market size was valued at USD 17.4 billion in 2025 and is projected to grow from USD 19.8 billion in 2026 to USD 51.2 billion by 2033, at a CAGR of 14.5% from 2026 to 2033. North America dominated the global market, accounting for a revenue share of 40.0% in 2025. The rising incidence of genetic disorders across the globe and increasing advancements in nucleic acid therapeutics are major market drivers.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Growing regulatory approval, rapidly expanding pipeline of gene & RNA based therapy, and robust expansion of the genomics research sector & strong traction gained by custom oligonucleotides are key major factors driving the market growth over the forecast period. The growing number of global CDMOs, adoption of a one-stop-shop model & foreign direct investments for nucleic acid therapeutics, and rising need for personalized medicine are other aspects anticipated to propel overall market revenue growth.

The growing incidence of genetic disorders globally has fueled interest in nucleic acid therapeutics as a potential option for the treatment of such conditions. For instance, according to WHO, as of 2023, there are around 10,000 types of distinct monogenic or single-gene diseases globally. Such conditions are caused due to mutations in a single gene. Thus, increasing the utilization of genetic materials such as RNA or DNA can prevent and treat genetic diseases. Genetic editing and sequencing technologies have significantly enhanced the comprehension of genetic diseases and considerably increased the development of nucleic acid therapeutics. Moreover, these drugs have high potential in treating rare genetic diseases for which the development process of traditional medicine is economically challenging. The high proficiency of nucleic acid therapeutics allows for a more precise and personalized treatment approach by specifically targeting the genetic abnormalities of the condition. Thus, the rising prevalence of genetic ailments is one of the prominent factors driving the growth in demand for nucleic acid therapeutics, thereby proliferating overall market demand.

To learn more about this report, Download Free Sample Report

The genomics research industry is witnessing a robust expansion driven by the growing demand for personalized medicine and technological advancements. This can be attributed to the growing adoption of advanced bioinformatics tools and high-throughput sequencing technologies. Custom oligonucleotides and short DNA or RNA sequences tailored for specific applications have gained significant traction in this market. Such molecular tools are pivotal in several genomic applications, including PCR amplification, DNA sequencing, and gene editing. Modifying oligonucleotides permits researchers to manipulate and accurately target genetic material, allowing enhanced precision and experimentation. This approach has witnessed considerable attention due to its potential to target several conditions, such as cancer, genetic ailments, and infectious diseases. Owing to the aforementioned factors, several biopharmaceutical companies have been focusing on developing novel nucleic acid therapeutics, including oligonucleotide products, over the past few years. Moreover, considerable investments are expected to be made for developing nucleic acid drugs, and a strong pipeline of products is anticipated to be commercialized during the forecast period.

There has been an increase in the outsourcing of biologics manufacturing due to COVID-19. As per the BioPlan Associates 17th Annual Report and Survey of Biopharmaceutical Manufacturing, 65% of biotherapeutics facilities used contract development and manufacturing services for at least some of their bioprocessing, which accelerated the market demand during the pandemic. Moreover, service providers, such as CROs and CDMOs, witnessed a spike in inquiries and orders, mostly related to coronavirus vaccines & therapeutics.

Innovations and speed-to-clinic are of critical importance for various biopharmaceutical and pharmaceutical companies. Specialty biopharmaceutical players and small companies significantly focus on delivering these important requirements within the industry. Several CDMOs and CROs act as one-stop-shop organizations. The service model of a one-stop-shop CDMO involves handling everything from API to dosage form and early development to commercialization. To offer such services, CDMOs must have a wide range of specialized handling capabilities and enabling technologies to address specific problem statements. Moreover, there is a wide range of product design capabilities among CDMO players that can be crucial in scaling a product concept and bringing it to the market.

Market Dynamics

The nucleic acid therapeutics CDMO market is entering a high-growth phase driven by increasing commercialization of RNA therapeutics, gene therapies, antisense oligonucleotides (ASOs), and mRNA-based medicines. As drug developers increasingly outsource complex manufacturing activities, demand for specialized CDMOs with expertise in oligonucleotide synthesis, LNP formulation, analytical testing, and GMP manufacturing continues to rise. The industry is also witnessing substantial investments in manufacturing capacity, technology upgrades, and strategic acquisitions as CDMOs race to address growing clinical and commercial demand.

Market Concentration & Characteristics

The market growth stage is high, and the pace is accelerating. The market is characterized by evolving technologies, regulatory considerations, materials innovation, and increasing globalization and outsourcing of manufacturing processes to leverage cost advantages and specialized capabilities.

The market fortifies a high degree of innovation. Innovation in nucleic acid therapeutics is becoming more important to treat numerous diseases, as it supports healthcare by establishing a pathway for advanced therapeutic products. Rapid technological development in gene editing, RNA interference (RNAi), and messenger RNA (mRNA) technologies drive innovation in nucleic acid therapeutics, thereby accelerating demand for CDMOs.

To learn more about this report, Download Free Sample Report

The market is witnessing a high level of M&A Activities to extend global capabilities in manufacturing and strengthen the current contract development and manufacturing services. The growing need to enhance capabilities and expand service portfolios propels consolidation in the market through mergers and acquisitions.

Regulations and restrictions on clinical trials are rapidly accelerating the need for continual monitoring by regulatory authorities & clinical teams to maintain study integrity. Furthermore, the time and cost associated with obtaining regulatory approvals for new therapeutics influence the speed of bringing products to market. Compliance with rigorous regulatory standards set by agencies like the U.S. FDA, EMA, and several others ensures the safety and efficacy of nucleic acid therapeutics, impacting the cost and complexity of manufacturing processes.

Service expansion in the market is medium owing to increasing demand for end-to-end services, from drug discovery and development to manufacturing and packaging, which drives CDMOs to expand their service portfolios. Further, growing demand from biotech and pharmaceutical companies for specialized services in nucleic acid therapeutics stimulates CDMOs to expand their capabilities.

Market players leverage this strategy to increase manufacturing capabilities and enhance the geographic reach of their products. Growing healthcare infrastructure and increasing investment in biotech research in regions such as Asia-Pacific and Latin America drive CDMOs to expand geographically. In addition, regional expansions provide access to skilled labor and scientific talent, essential for innovation and high-quality manufacturing. Thus, they positively impact the overall market progression.

Analyst Perspective

By 2033, competitive differentiation is expected to be driven by investments in manufacturing scale, LNP delivery technologies, advanced analytics, and integrated end-to-end CDMO capabilities. Providers offering seamless development-to-commercialization support, regulatory expertise, and scalable production platforms will be best positioned to capitalize on growing outsourcing demand. Despite ongoing challenges related to manufacturing complexity and regulatory compliance, the market outlook remains strong, supported by increasing adoption of specialized CDMO services for next-generation nucleic acid therapeutics.

Type Insights

Based on type, the RNA-based therapies segment led the market with the largest revenue share of 65.6% in 2025. The demand for RNA-based therapies is expected to surge due to promising clinical trial outcomes and the potential to address a range of diseases. Hence, these therapies are currently in the highlight as the biopharma industry players emphasize RNA-based therapies in their future pipelines to meet rising healthcare demand.

The gene therapy segment is expected to witness the fastest CAGR over the forecast period, due to the potential of gene therapy candidates to treat several disorders. For instance, in January 2023, Vector BioMed secured USD 15 million in its initial round of funding, marking a significant milestone for the startup. With the raised capital, the company aimed to address a substantial void in the production of cell and gene therapies. Further, with rising demand for robust disease treatment therapies, companies are accelerating Research & Development (R&D) efforts for effective gene therapies that target the cause of disease at a genomic level, which further propel industry progression.

Service Insights

Based on service, the manufacturing services segment accounted for the largest market share in 2025. The high segmental growth is attributed to the increasing highly specialized knowledge and expertise in the manufacturing of nucleic acid therapies. Moreover, CDMOs that focus on nucleic acid manufacturing have a deep understanding of these therapies, giving them a competitive advantage in the market. Besides, major CDMOs are undertaking substantial investments to expand their capacity and meet rising demand. For instance, in March 2024, Lonza announced the acquisition of a large-scale biologics manufacturing site from Roche in the U.S. The deal is worth USD 1.2 billion; through this acquisition, Lonza received access to one of the world's largest biologics manufacturing sites by volume to cater to its customer's needs. The investment undertaken by Lonza positioned the company to offer customers a fully integrated end-to-end solution. In addition, a growing number of nucleic acid therapeutics projects is another key factor aiding segment growth.

The process development and optimization segment is anticipated to witness at a significant CAGR over the forecast period. The segment growth potential is owing to the growing pipeline of nucleic acid therapeutics, with numerous candidates in various stages of clinical development, which fuels the demand for CDMO services. According to the American Society of Gene & Cell Therapy (ASGCT), there are 3,866 therapies in various stages of development, spanning from preclinical to preregistration phases. Around 2,082 therapies fall under gene therapies, including genetically modified cell therapies like CAR T-cell therapies. This accounts for 53% of the overall development of gene, cell, and RNA therapies. As a result, companies are seeking expertise in process development & optimization to scale up production for clinical trials and commercialization, thereby witnessing segmental market growth.

End-use Insights

Based on end-use, the biotech companies segment held the highest market share in 2025. Some of the key factors contributing to segment growth are expertise in nucleic acid-based drug development, rising substantial investment for nucleic acid therapies across emerging countries, increasing R&D of innovative therapies, and expanding product portfolio. In addition, the promising advantages of therapies to cure various disorders are expected to fulfill unmet medical needs. Moreover, the adoption of emerging technologies and growing product approval & launches the segment growth.

The government & academic research institutes segment is anticipated to grow at the fastest CAGR over the forecast period. The segment is expected to witness growth at a significant pace due to increasing early-stage research & innovation, supported by significant investment and funding for drug development initiatives. For instance, in June 2022, Evonik announced a substantial investment of USD 220 million in collaboration with the U.S. government to establish a new lipid production facility dedicated to mRNA-based therapies in the U.S. Hence, adoption of such strategies is likely to impact segmental growth positively.

Application Insights

Based on application, the genetic disorders segment dominated the nucleic acid therapeutics CDMO market in 2025. Growth in the segment can be attributed to the increasing prevalence of genetic disorders and favorable government initiatives. Moreover, gene therapy support provides treatments for several disorders that currently have limited or no available treatments in the market. This factor created new possibilities for innovative therapy products targeting specific genetic mutations, further debilitating genetic conditions. Hence, the segment offers the unique potential to cure a genetic disease that impacts millions of patients positively.

To learn more about this report, Download Free Sample Report

The Infectious disease segment is expected to grow at a significant CAGR during the forecast period, primarily fueled by escalating application of these therapeutics in treating COVID-19 infections. The emergence of the COVID-19 pandemic has led to a paradigm shift in the research landscape, with a notable increase in the utilization of nucleic acid therapeutics for infectious diseases. Moreover, the momentum gained during the pandemic has positioned the infectious disease segment as a focal point for market growth, with ongoing endeavors focused on addressing a broader spectrum of infectious diseases beyond COVID-19.

Regional Insights

North America dominated the nucleic acid therapeutics CDMO market, accounting for a revenue share of 40.0% in 2025. This can be attributed to a proactive regulatory environment, increasing investment & funding support, and a growing number of product approvals globally. Other factors contributing to the growth are increased R&D activities, the growing prevalence of chronic diseases, and increased government support for the healthcare sector. Moreover, the robust biotech industry, global expansion of CDMOs, presence of key CDMOs, advanced healthcare ecosystem, solid clinical trial infrastructure, and strong academic & research institutions are other factors boosting the market growth.

To learn more about this report, Download Free Sample Report

U.S. Nucleic Acid Therapeutics CDMO Market Trends

The nucleic acid therapeutics CDMO market in the U.S. held the largest share in North America in 2025, owing to a strong presence of industry participants in the country. The U.S. market has benefited from the immense potential of nucleic acid therapeutics to treat a range of diseases such as oncology, genetic disorders, infectious diseases, and others. Moreover, increasing investments, a rising number of clinical trials, rapid advancements in medicine development, and a growing gene therapy pipeline across the country are expected to drive the market growth.

Europe Nucleic Acid Therapeutics CDMO Market Trends

The nucleic acid therapeutics CDMO market in Europe is expected to grow at a significant CAGR during the forecast period, owing to the presence of key pharmaceutical and biotechnology companies in this region. In addition, there are a large number of CDMOs specializing in therapy innovation in various European countries, such as Germany, the UK, and France, which is expected to contribute to market growth in this region.

The UK nucleic acid therapeutics CDMO market held the largest share in Europe in 2024. The growth can be attributed to various factors such as the presence of various multinational CDMOs, significant R&D spending, healthcare research, and rapidly evolving therapeutic approaches with developments of gene therapies, modified nucleotides, circular RNA, self-amplifying RNA, and tissue targeting have fueled the demand for UK nucleic acid therapeutics CDMOs.

The nucleic acid therapeutics CDMO market in Germany is anticipated to grow at a significant CAGR over the forecast period. Technological advancements and quality clinical resources are some of the primary factors expected to propel market growth over the forecast period. Moreover, government initiatives for clinical research activities have accelerated the market growth in Germany.

Asia Pacific Nucleic Acid Therapeutics CDMO Market Trends

The nucleic acid therapeutics CDMO market in Asia Pacific is expected to grow at the fastest CAGR over the forecast period. The high market growth potential is attributed to the changing business model of MNC outsourcing, and R&D activities are expected to increase nucleic acid therapeutics CDMO demand in Asia Pacific owing to cost-efficiency offered by CDMO in countries such as India and China. These countries are expected to witness lucrative market growth. In contrast, countries such as South Korea, Australia, and Thailand are also expected to witness steady growth over the forecast period. The establishment of several CDMOs across the Asia Pacific region has also strengthened innovation in therapies in the region.

The China nucleic acid therapeutics CDMO market held the largest share in Asia Pacific in 2024. The market growth is owing to the increasing number of nucleic acid therapeutics approvals due to their potential to become blockbuster drugs for treating a range of diseases, including cardiovascular and metabolic diseases, liver diseases, and a variety of rare diseases.

The nucleic acid therapeutics CDMO market in Japan is expected to grow at the fastest CAGR over the forecast period, due to various factors such as the growing pharmaceutical industry, increasing demand for outsourcing services, and rising R&D activities.

India nucleic acid therapeutics CDMO market is anticipated to grow at the fastest CAGR over the forecast period. Growth in the country can be attributed to the availability of low-cost labor, low manufacturing costs, considerable demand for high-quality medications, and strong presence of WHO-cGMP-compliant facilities & a skilled workforce.

Latin America Nucleic Acid Therapeutics CDMO Market Trends

The nucleic acid therapeutics CDMO market in Latin America is anticipated to grow at a substantial CAGR over the forecast period, owing to the expanding CDMO industry, which reduces the monitoring cost associated with outsourcing services. Moreover, growing approval for gene therapy, rising investments in R&D research, and increasing product launches are expected to drive the market growth in the region.

The Brazil nucleic acid therapeutics CDMO market is anticipated to grow at a significant CAGR over the forecast period. The growing prevalence of blood cancer, genetic disorders, and infectious diseases in the region has created a requirement for nucleic acid therapeutics CDMO. This has led to the business expansion of gene therapy products, creating substantial demand for the market in recent years.

MEA Nucleic Acid Therapeutics CDMO Market Trends

The nucleic acid therapeutics CDMO market in MEA is expected to grow at a substantial CAGR over the forecast period. Several companies in the region are innovating nucleic acid therapeutics due to growing concerns about treating various chronic & genetic disorders and increasing government support to attract CDMO companies to further innovate various vaccines & therapeutics for the patient population.

South Africa nucleic acid therapeutics CDMO market is anticipated to grow at the fastest CAGR over the forecast period, owing to growing demand for nucleic acid therapeutics to treat various chronic & genetic disorders, approval of products, and expansion of CDMO manufacturing sites. In addition, the country is the largest market for pharmaceuticals in the sub-Saharan African region. It has one of the most developed infrastructure facilities with the presence of a significant number of life sciences companies.

Key Nucleic Acid Therapeutics CDMO Company Insights

The prominent market players operating across the global market focus on implementing numerous strategic initiatives such as acquisitions, mergers, service launches, partnerships, expansions, and collaborations, among others, to broaden the geographical reach and gain a competitive edge in the overall market. For instance, in November 2023, LGC’s unit LGC Biosearch Technologies acquired PolyDesign, a leading manufacturer & supplier of solid support embedded frits used for low- & ultra-low-scale DNA & RNA oligonucleotide synthesis & purification. Such acquisition broadened the service offerings of the company in a significant market.

Recent Developments

• In October 2026, Agilent Technologies, Inc. expanded its oligonucleotide manufacturing capabilities with additional laboratory space in Boulder, Colorado. The facility is intended to support the development and scale-up of emerging oligonucleotide manufacturing technologies, initially focusing on enzymatic ligation.

• In September 2026, Aldevron and Integrated DNA Technologies (IDT) launched research-grade Cas9 mRNA solutions in wild-type and SpyFi high-fidelity formats. The joint offering combines IDT's CRISPR engineering and analysis expertise with Aldevron's mRNA manufacturing capabilities, supporting gene-editing research and the advancement of nucleic acid-based therapeutics toward clinical development.

Global Nucleic Acid Therapeutics CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global nucleic acid therapeutics CDMO market report based on type, service, end-use, application, and region:

• Type Outlook (Revenue, USD Million, 2021- 2033)

  • Gene Therapy

  • RNA-based Therapies

• Service Outlook (Revenue, USD Million, 2021- 2033)

  • Process Development and Optimization

  • Manufacturing Services

  • Analytical and Quality Control Services

  • Others

• End-use Outlook (Revenue, USD Million, 2021- 2033)

  • Pharmaceutical Companies

  • Government & Academic Research Institutes

  • Biotech Companies

• Application Outlook (Revenue, USD Million, 2021- 2033)

  • Rare Diseases

  • Genetic Disorders

  • Infectious Diseases

  • Others

• Regional Outlook (Revenue, USD Million, 2021- 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

Delivered Customizations

This report has been delivered with the following In-depth customizations